| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 3 | +6.58M | 97.6% | $6.85 | +$45.1M |
| Sells | 5 | -163K | 2.4% | $14.92 | -$2.43M |
| Net | -2 | +6.42M | 95.2% | +$42.7M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10%+ Owner | $179M | +$15.1M | +9.18% | Oct 12, 2023 |
| Samsara BioCapital GP, LLC | 10%+ Owner | $108M | +$15M | +16.1% | Oct 16, 2023 |
| Siren, L.L.C. | 10%+ Owner | $101M | Jul 25, 2024 | ||
| Srinivas Akkaraju | Director | $61.1M | +$15M | +32.5% | Jun 27, 2024 |
| Kristina Burow | Director | $21.2M | Jun 27, 2024 | ||
| Nagesh K. Mahanthappa | Interim CEO and President | $7.65M | Jun 16, 2022 | ||
| Jay T. Backstrom | CHIEF EXECUTIVE OFFICER, Director | $5.55M | -$183K | -3.19% | Feb 16, 2024 |
| Yung H. Chyung | Chief Medical Officer | $4.12M | Feb 14, 2022 | ||
| David Hallal | Director | $2.73M | Jun 27, 2024 | ||
| Gregory John Carven | Chief Scientific Officer | $2.04M | Jun 16, 2022 | ||
| Junlin Ho | General Counsel | $1.83M | -$164K | -8.2% | Jun 17, 2024 |
| Edward H. Myles | Coo & Cfo | $1.81M | -$1.37M | -43.2% | Jun 17, 2024 |
| Caryn Parlavecchio | Chro | $1.42M | -$157K | -9.95% | Aug 16, 2024 |
| Mo Qatanani | Chief Scientific Officer | $1.3M | -$553K | -29.8% | Jun 17, 2024 |
| Jing L. Marantz | Chief Medical Officer | $1.16M | Feb 12, 2024 | ||
| Tracey Sacco | Chief Commercial Officer | $785K | Feb 12, 2024 | ||
| Amir Nashat | Director | $608K | May 9, 2024 | ||
| Michael Gilman | Director | $458K | Jun 27, 2024 | ||
| Jeffrey S. Flier | Director | $402K | Jun 27, 2024 | ||
| Katie Peng | Director | $281K | Jun 27, 2024 | ||
| Akshay Vaishnaw | Director | $206K | Jun 27, 2024 | ||
| Joshua Reed | Director | $121K | Jun 27, 2024 | ||
| Richard Brudnick | Director | $121K | Jun 27, 2024 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|